



## CryoLife Conducts Cardiac Allograft Symposium

October 19, 2006

ATLANTA, Oct. 19 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY) a biomaterials and biosurgical device company, announced today that it is conducting a cardiac reconstruction symposium focusing on the use of human heart valves and tissues at its corporate headquarters training facility in Kennesaw, GA, October 19-21. The program includes the following: current indications and clinical outcomes, surgical techniques associated with the implantation of aortic and pulmonary allografts, and advances in tissue engineering related to cardiac reconstruction.

Steven G. Anderson, President and CEO of CryoLife, Inc., stated, "As leaders in human tissue transplantation used for cardiac reconstruction in women and children, we are excited to host this advanced surgical training at our state-of-the-art facility and laboratory. Attendees will have the unique opportunity to learn the latest techniques in reconstructive heart surgery utilizing human aortic and pulmonary valves from some of the world's most renowned cardiovascular surgeons."

The symposium's distinguished faculty includes: Sir Professor Magdi Yacoub, FRS, a pioneer in the field of heart transplantation, Chairman of The Magdi Yacoub Institute at The Imperial Hospital Heart Science Center, London, U.K.; Ronald C. Elkins, M.D., Professor Emeritus, Thoracic and Cardiovascular Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, and a member of CryoLife's Board of Directors; Francis Robicsek, M.D., Ph.D., Chairman, Department of Thoracic and Cardiovascular Surgery, Carolinas Medical Center, Charlotte, NC; Paul E. Stelzer, M.D., Associate Professor of Surgery, Albert Einstein College of Medicine, Beth Israel Medical Center, New York, NY; and Kenton J. Zehr, M.D., Chief of Cardiac Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.

The program director is John W. Brown, M.D., Professor of Cardiothoracic Surgery, Indiana University School of Medicine, Indianapolis, IN. David M. Fronk, Vice President, Regulatory Affairs and Quality Assurance at CryoLife, and Steven Goldstein, Ph.D., Senior Director, Tissue Technologies at CryoLife, are also on the faculty. Some 40 surgeons from around the United States are expected to participate in the symposium.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiovascular, vascular, and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels and is CE marked in the European Community and approved in Canada for use in soft tissue repair and approved in Australia for use in vascular and pulmonary sealing and repair. The Company also distributes the CryoLife- O'Brien(R) stentless porcine heart valve and the SG Model 100 vascular graft, which are CE marked for distribution within the European Community.

For additional information about the company, visit CryoLife's Web site:  
<http://www.cryolife.com>

Media Contacts:

D. Ashley Lee,  
Executive Vice President, Chief Financial Officer and Chief Operating Officer  
Phone: 770-419-3355

Katie Brazel  
Fleishman Hilliard,  
Phone: 404-739-0150

SOURCE CryoLife, Inc.